Compare Mani, Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 15.78% CAGR growth in Net Sales over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 15.78% over the last 5 years
3
Flat results in May 26
4
With ROE of 10.62%, it has a expensive valuation with a 3.14 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 166,925 Million (Small Cap)
30.00
NA
0.00%
-0.41
11.27%
2.92
Revenue and Profits:
Net Sales:
8,290 Million
(Quarterly Results - May 2026)
Net Profit:
1,744 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.69%
0%
-8.69%
6 Months
-2.93%
0%
-2.93%
1 Year
17.82%
0%
17.82%
2 Years
-20.67%
0%
-20.67%
3 Years
-18.42%
0%
-18.42%
4 Years
-7.19%
0%
-7.19%
5 Years
-34.03%
0%
-34.03%
Mani, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.78%
EBIT Growth (5y)
16.64%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.55
Tax Ratio
33.85%
Dividend Payout Ratio
82.74%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
27.23%
ROE (avg)
11.30%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
3.14
EV to EBIT
16.99
EV to EBITDA
13.34
EV to Capital Employed
4.58
EV to Sales
4.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
26.94%
ROE (Latest)
10.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Aug 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - May'26 - QoQ
May'26
Nov'25
Change(%)
Net Sales
8,290.00
7,828.00
5.90%
Operating Profit (PBDIT) excl Other Income
3,002.00
2,862.00
4.89%
Interest
0.00
0.00
Exceptional Items
0.00
16.00
-100.00%
Consolidate Net Profit
1,744.00
1,896.00
-8.02%
Operating Profit Margin (Excl OI)
288.20%
288.10%
0.01%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Aug'25
Aug'25
Aug'24
Change(%)
Net Sales
29,968.00
28,513.00
5.10%
Operating Profit (PBDIT) excl Other Income
10,665.00
10,662.00
0.03%
Interest
3.00
6.00
-50.00%
Exceptional Items
-1,175.00
-70.00
-1,578.57%
Consolidate Net Profit
4,643.00
6,286.00
-26.14%
Operating Profit Margin (Excl OI)
273.40%
294.30%
-2.09%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2025 is 5.10% vs 16.44% in Aug 2024
Consolidated Net Profit
YoY Growth in year ended Aug 2025 is -26.14% vs 5.59% in Aug 2024
About Mani, Inc. 
Mani, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






